Previous 10 | Next 10 |
2023-11-08 16:43:55 ET More on Ligand Pharmaceuticals Ligand: Nothing Exciting Stands Out Ligand Pharmaceuticals Q3 2023 Earnings Preview Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid Therapeutics for $30M Seeking Alpha’s Quant...
Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine month...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Ligand Pharmaceuticals Incorporated (LGND) is expected to report $0.36 for Q3 2023
2023-11-07 12:10:02 ET More on Ligand Pharmaceuticals Ligand: Nothing Exciting Stands Out Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid Therapeutics for $30M Ligand Pharmaceuticals closes acquisition of assets of Novan Seeking Alpha...
COLUMBUS, Ohio, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that a case report detailing a durable compl...
2023-11-05 23:46:57 ET In the upcoming week of November, investors can anticipate a flurry of quarterly reports from major companies, promising significant market activity. Notable among them is Disney ( NYSE: DIS ), a household name set to disclose its financial performance. ...
2023-11-01 08:34:25 ET More on Ligand Pharmaceuticals Ligand: Nothing Exciting Stands Out Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid Therapeutics for $30M Ligand Pharmaceuticals closes acquisition of assets of Novan For further det...
TZIELD is the first and only FDA approved treatment to delay the onset of Stage 3 type 1 diabetes Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has acquired Tolerance Therapeutics, Inc. (“Tolerance Therapeutics”) for $20 million in cash. To...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will report third quarter 2023 financial results after the close of the U.S. financial markets on Wednesday, November 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a ge...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...